Identifying menopause in breast cancer patients: Considerations and implications

Breast Cancer Research and Treatment

Volumn 104, Issue 2, 2007, Pages 115-120

  Clemons, Mark ^a   Simmons, Christine ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Amenorrhea; Aromatase inhibitors; Breast cancer; Menopause; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; ESTRADIOL; EXEMESTANE; FLUOROURACIL; FOLLITROPIN; GONADORELIN DERIVATIVE; GOSERELIN; LETROZOLE; LUTEINIZING HORMONE; METHOTREXATE; PROGESTERONE; PROLACTIN; TAMOXIFEN; TOREMIFENE;

AMENORRHEA; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; DRUG SUBSTITUTION; FEMALE INFERTILITY; HORMONAL THERAPY; HUMAN; MENOPAUSE; MENSTRUAL CYCLE; MONOTHERAPY; OVULATION INDUCTION; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MENOPAUSE; NEOPLASMS, HORMONE-DEPENDENT;

EID: 34447520522     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9401-y     Document Type: Review

References (34)

1. Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344:276-285
2. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 365:1687-1717
3. Clemons M, Coleman RE, Verma S (2004) Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard? Cancer Treat Rev 30:325-332
4. Freedman OC, Verma S, Clemons MJ (2005) Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution? Cancer Treat Rev 31:1-17
5. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryan J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for post-menopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619-629
6. Gainford MC, McCready D, Cohen Z, Clemons M (2006) The latest is the greatest? Results of a structured lecture about aromatase inhibitor use for breast cancer. Breast Cancer Res Treat 96(3):203-206
7. Genuth SM (1990) Female reproduction. In: Berne RM, Levy MN (eds) Principle of physiology. Wolfe Publishing Ltd, London, pp. 599-615
8. Treloar AE, Boynton RE, Behn BG, Brown BW (1967) Variation of the human menstrual cycle through reproductive life. Int J Fertil 12:77-126
9. Sherman BM, Korenman SG (1975) Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 55:699-706
10. Shideler SE, DeVane GW, Kalra PS, Benirschke K, Lasley BL (1989) Ovarian-pituitary hormone interactions during the perimenopause. Maturitas 11:331-339
11. Trevoux R, De Brux J, Castanier M, Nahoul K, Soule JP, Scholler R (1986) Endometrium and plasma hormone profile in the peri-menopause and post-menopause. Maturitas 8:309-326
12. Metcalf MG, Donald RA, Livesey JH (1981) Pituitary-ovarian function in normal women during the menopausal transition. Clin Endocrinol (Oxf) 14:245-255
13. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in pre-menopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729
14. Burstein HJ, Winer EP (2000) Primary care for survivors of breast cancer. N Engl J Med 343:1086-1094
15. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N (1999) Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 17(8):2365-2370
16. Bhatavdekar JM, Shah NG, Patel DD, Karelia NH, Trivedi SN, Vora HH, Ghosh N, Giri DD, Balar DB (1992) Endocrine function in pre-menopausal and post-menopausal advanced breast cancer patients treated with CMF or tamoxifen. Neoplasma 39:123-127
17. Delrio G, De Placido S, Pagliarulo C, d'Istria M, Fasano S, Marinelli A, Citarella F, De Sio L, Contegiacomo A, Iaffaioli RV (1986) Hypothalamic- pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori 72:53-61
18. Groom GV, Griffiths K (1976) Effect of the anti-estrogen tamoxifen on plasma levels of luteinizing hormone, follicle-stimulating hormone, prolactin, estradiol and progesterone in normal pre-menopausal women. J Endocrinol 70:421-428
19. West CP, Baird DT (1987) Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. Clin Endocrinol (Oxf) 26:213-220
20. Buzzoni R, Biganzoli L, Bajetta E, Celio L, Fornasiero A, Mariani L, Zilembo N, Di Bartolomeo M, Di Leo A, Arcangeli G, Aitini E, Farina G, Schieppati G, Galluzzo D, Martinetti A (1995) Combination goserelin and tamoxifen therapy in pre-menopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology. Br J Cancer 71:1111-1114
21. Robertson JF, Blamey RW (2003) The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and peri-menopausal women. Eur J Cancer 39:861-869
22. Tredway DR, Buraglio M, Hemsey G, Denton G (2004) A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, pre-menopausal female volunteers. Fertil Steril 82:1587-1593
23. Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z (2005) Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23:4347-4353
24. Smith IE, Dowsett M, Yap TS, Walsh G, Lonning PE, Santen RJ, et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea; caution and suggested guidelines. J Clin Oncol 24(16):2444-2447
25. Carlson RW, Schurman CM, Rivera E, Chung CT, Phan S-C, Dice EK, Arun B, Thomas E, Valero V (2004) Goserelin plus anastrozole for the treatment of pre-menopausal women with hormone receptor positive, recurrent/metastatic breast cancer. Breast Cancer Res Treat 88:S237
26. Forward DP, Cheung KL, Jackson L, Robertson JFR (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for pre-menopausal advanced breast cancer. Br J Cancer 90:590-594
27. National Comprehensive Cancer Network (2005) NCCN practice guidelines in oncology v.1.2005: breast cancer. http://www.nccn.org
28. World Health Organization (1981) Technical report series: research on the menopause. WHO Technical Report Series No. 670. Geneva, Switzerland
29. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in post-menopausal women with primary breast cancer. N Engl J Med 350:1081-1092
30. Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Propiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Dsitante V, Amadori D, Sismondi P (2005) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23:5138-5147
31. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingstone RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in post-menopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
32. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J (2005) Switching of post-menopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455-462
33. The ATAC Trialists' Group (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of post-menopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131-2139
34. Cooper GS, Baird DD, Darden FR (2001) Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population-based study of women aged 35-49 years. Am J Epidemiol 153:1159-1165